Anika Therapeutics, Inc.
ANIK · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $28 | $28 | $26 | -$1 |
| % Growth | -1.4% | 7.8% | 2,128.5% | – |
| Cost of Goods Sold | $12 | $14 | $11 | -$24 |
| Gross Profit | $16 | $14 | $15 | $23 |
| % Margin | 56% | 50.9% | 56.1% | -1,749.2% |
| R&D Expenses | $7 | $6 | $6 | $3 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $12 | $12 | $13 | -$5 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | -$3 |
| Operating Expenses | $19 | $19 | $19 | -$5 |
| Operating Income | -$3 | -$4 | -$4 | $28 |
| % Margin | -11.6% | -14.8% | -16.4% | -2,156.4% |
| Other Income/Exp. Net | $1 | $0 | $0 | $1 |
| Pre-Tax Income | -$2 | -$4 | -$4 | $29 |
| Tax Expense | $1 | $1 | $0 | $3 |
| Net Income | -$2 | -$4 | -$5 | -$22 |
| % Margin | -8.4% | -14.1% | -18.6% | 1,695% |
| EPS | -0.16 | -0.28 | -0.34 | -1.5 |
| % Growth | 42.9% | 17.6% | 77.3% | – |
| EPS Diluted | -0.16 | -0.28 | -0.34 | -1.5 |
| Weighted Avg Shares Out | 14 | 14 | 14 | 15 |
| Weighted Avg Shares Out Dil | 14 | 14 | 14 | 15 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | – | $0 |
| Interest Expense | $0 | $0 | – | $0 |
| Depreciation & Amortization | $1 | $1 | $2 | $2 |
| EBITDA | -$1 | -$3 | -$3 | $27 |
| % Margin | -3% | -9.8% | -10.3% | -2,056.5% |